Compare Global X Copper Miners ETF (COPX) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Quest Diagnostics Inc — how do they compare? Global X Copper Miners ETF trades at $78, while Quest Diagnostics Inc trades at $205.45 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Global X Copper Miners ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals.
| COPX | DGX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $216.02 |
52-Week Low | $42.75 | $166.42 |
Market Cap | — | $22.80B |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $74.35, down 2.86% amid bearish technical signals with all 16 moving average indicators signaling sell. The ETF provides exposure to copper mining companies benefiting from AI-driven electrification demand, though key financial ratios remain undisclosed in current data. Recent news highlights copper's structural role in AI infrastructure and energy transition.
Outlook hinges on copper supply-demand dynamics amplified by AI data center expansion, though technical weakness suggests near-term pressure. Risks include commodity price volatility and execution challenges in mining supply chains. Analyst sentiment remains constructive on long-term copper fundamentals despite current bearish technical positioning.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
